Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
| ▸ | GABRP | O00591 | 1/20 | 0.37 |
| ▸ | GABRD | O14764 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.37 |
| ▸ | GABRE | P78334 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.37 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.37 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28914966 | 0.98 | CHRM3 (0.38) | CHRM3GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL27761386 | 0.93 | CYP19A1 (0.39) | CHRM3GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL27653752 | 0.88 | SLC6A1 (0.33) | CHRM3GABRA1GABRA5GABRB2GABRA4 | |
| SCHEMBL20617836 | 0.88 | SLC6A1 (0.33) | CHRM3GABRA1GABRA5GABRB2GABRA4 | |
| SCHEMBL27598186 | 0.88 | SLC6A1 (0.33) | CHRM3GABRA1GABRA5GABRB2GABRA4 | |
| SCHEMBL17886845 | 0.84 | CYP19A1 (0.41) | CHRM3CYP19A1EPHX1 | |
| SCHEMBL14648562 | 0.84 | GABRP (0.34) | CHRM3GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL13641699 | 0.81 | TPSAB1 (0.34) | CHRM3GABRA1TSHRGABRG2GABRB3 | |
| SCHEMBL28801029 | 0.81 | ATM (0.34) | CHRM3CHRM2CHRM1 | |
| SCHEMBL13073268 | 0.80 | CYP19A1 (0.46) | CHRM3CYP19A1EPHX1CHRM2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567498-A | Sodium hydride suspension and application thereof in flow chemical reaction | 武汉药明康德新药开发有限公司 | 2024-02-20 | — | — | CN | claimed |
| CN-117069063-A | Sodium hydride suspension and application thereof in flow chemical reaction | 武汉药明康德新药开发有限公司 | 2023-11-17 | — | — | CN | claimed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | claimed |
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| CN-102236253-B | Multi-phase high-silicon photoresist imaging method for micro-photoetching process, multi-phase high-silicon photoresist and use | WEIFANG XINGTAIKE MICROELECTRONIC MATERIALS CO LTD | 2012-11-07 | — | — | CN | claimed |
| CN-102236253-A | Multi-phase high-silicon photoresist imaging method for micro-photoetching process, multi-phase high-silicon photoresist and use | WEIFANG XINGTAIKE MICROELECTRONIC MATERIALS CO LTD | 2011-11-09 | — | — | CN | claimed |
| CN-117658986-A | Preparation method of AR antagonist TRC-253 | 湖南师范大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-117567498-A | Sodium hydride suspension and application thereof in flow chemical reaction | 武汉药明康德新药开发有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117069063-A | Sodium hydride suspension and application thereof in flow chemical reaction | 武汉药明康德新药开发有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-1615306-A | C-5 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2005-05-11 | — | — | CN | disclosed |
| CN-1509286-A | Metalloprotease inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
| CN-1290266-A | Benzofuran-4-carboxamides and their therapeutical use | DARWIN DISCOVERY LTD (GB) | 2001-04-04 | — | — | CN | disclosed |
| CN-1211991-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1999-03-24 | — | — | CN | disclosed |
| CN-1125575-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1996-07-03 | — | — | CN | disclosed |
| CN-1111630-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1995-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | CHRM3 2057/4885GABRA1 4423/4885TSHR 4479/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | CHRM3 355/4885GABRA1 909/4885TSHR 1067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.